AcroViz

AcroViz

AcroViz provides the first-to-market microscopic brain axonal integrity assessment service that evaluate axonal degeneration, predicting brain diseases or mental disorders associated with dementia, such as Alzheimer’s Disease.
Clinical data validation has proven statistical significance in predicting the risk and prognosis of dementia, which serves as a Mild Cognitive Impairment (MCI) image biomarker.
AcroViz’s first product the Axonal Brain Age – Brain Health Report utilizes AcroViz’s core technology, diffusion magnetic resonance imaging, and machine learning techniques, to evaluate the robustness of whole-brain fiber tracts, as well as cognitive function networks.